查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1988242

Duchenne氏肌肉失养症治疗市场：按药物类别、剂型、给药途径、分销管道和最终用户划分－2026-2032年全球市场预测

Duchenne Muscular Dystrophy Drugs Market by Drug Class, Form, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，Duchenne氏肌肉失养症治疗市场价值将达到 18.5 亿美元，到 2026 年将成长至 20.2 亿美元，到 2032 年将达到 34.6 亿美元，复合年增长率为 9.31%。

主要市场统计数据
基准年 2025 18.5亿美元
预计年份：2026年 20.2亿美元
预测年份 2032 34.6亿美元
复合年增长率 (%) 9.31%

该计画总结了整个生态系统中的科学进展、临床重点和相关人员的需求，为Duchenne氏肌肉失养症。

Duchenne氏肌肉失养症仍然是临床和商业性最复杂的罕见疾病领域之一，其特征是进行性性肌肉退化，给看护者带来沉重负担，并且持续需要疾病修正治疗。过去十年来的科学进步已将该领域的治疗重点从对症治疗转向靶向分子干预，从而构建了一个紧密的治疗方法、监管合作和支付方参与策略的生态系统。临床医生、患者家属和政策制定者越来越关注药物的生物活性，同时也关注其带来的显着功能获益、长期安全性以及永续的用药模式。

医疗保健领域前所未有的科学、製造和价值导向的变革正在重塑Duchenne氏肌肉失养症治疗的临床开发、分销和报销策略。

近年来发生的变革性变化正在重新定义Duchenne氏肌肉失养症的治疗研发和实施方式，影响临床试验设计、药物生产和长期照护模式。科学创新使得针对该疾病潜在遗传缺陷的标靶治疗更加精准，从而从统一的治疗方法的研发路径。同时，测量科学也日趋成熟。新型功能性终点、数位生物标记和病患报告结局正被纳入关键的研发项目中，以便在小规模、异质性更高的群体中也能获得具有临床意义的益处。

本研究评估了预计 2025 年美国关税调整将如何影响Duchenne氏肌肉失养症治疗的供应链、製造在地化选择和市场进入策略。

贸易政策变化和关税考量是生物製药供应链策略规划的关键要素，而美国提案于2025年进行的关税调整将进一步增加Duchenne氏肌肉失养症治疗领域企业的营运风险。生物製药生产的原料，例如质体DNA、特殊试剂、一次性系统和腺相关病毒（AAV）生产原料，在其生产週期中往往需要多次跨境运输。因此，关税和海关重新分类可能导致总成本增加和前置作业时间延长，可能促使企业重新评估供应商的所在地。

透过将药物类别、分销管道、最终用户背景、剂型和给药途径整合到以细分主导的策略中，可以获得可操作的商业性和临床见解。

从多个临床和商业性观点审视治疗方法时，细分市场分析揭示了清晰的策略意义。药物类别、外显子跳跃剂、基因疗法和类固醇疗法都需要独特的临床开发模式和证据支持。在基因治疗领域，基于腺相关病毒（AAV）和非病毒载体的治疗方式之间的差异会影响载体选择、免疫抗原性管理和生产路线决策。进一步考虑AAV血清型选择，例如血清型6和血清型9，会影响组织标靶化、给药策略和生产规模的复杂性。对分销管道的检验突显了医院药房、线上药房和零售药房之间不同的物流和合规要求。每个管道在低温运输管理、报销和患者支援需求方面都面临着不同的挑战。从最终用户的观点来看，医疗保健环境中的要求与医院和专科诊所的要求有显着差异，这会影响培训、监测频率以及对输液相关事件的紧急应变准备。剂型和给药途径对药物诱导和患者依从性至关重要。胶囊和口服药片与注射和静脉注射相比，能为患者带来不同的体验，而且每种给药途径——肌肉注射、静脉注射和口服——都有其独特的临床监测和给药基础设施需求。

评估美洲、欧洲、中东和非洲以及亚太地区在监管、还款和营运方面的区域差异，并协助制定分阶段的市场进入和存取策略。

区域趋势影响Duchenne氏肌肉失养症治疗的部署和准入路径，每个地区都有其独特的法规、报销和营运考虑。在美洲，成熟的专科中心网路、完善的罕见疾病临床试验基础设施以及优先考虑医疗技术评估和基于价值的合约的支付方，共同影响着药物的核准顺序和商业性上市。在欧洲、中东和非洲，监管路径各不相同，报销决策通常受国家监管机构的影响。由于监管机构对疗效比较证据的要求各不相同，因此必须儘早协调不同的证据策略并建立区域特定的卫生经济学模型。在亚太地区，临床研究能力正在快速发展，与产业界合作的意愿日益增强，生产生态系统也不断多元化。然而，打入市场策略必须考虑到不同的监管要求、价格控制和患者准入计划。

本研究分析了企业在载体工程、生产规模化和相关人员合作方面的策略如何决定Duchenne氏肌肉失养症治疗的临床开发和商业化准备进展。

公司层面的发展趋势对Duchenne氏肌肉失养症治疗领域的创新步伐和方向至关重要。专注于外显子跳跃和小分子疗法的生物技术公司不断改进有效载荷的化学表征、递送方法和患者选择标准，以增强临床差异化。致力于基因替代疗法的机构则专注于载体工程、血清型选择和可扩展的GMP生产，以减少批次间差异并确保临床供应的稳定性。在整个产业中，策略联盟，例如研究合作、授权协议和生产伙伴关係，被广泛用于弥补能力差距并缩短临床试验週期。

透过采用结合早期生产规划、适应性证据产生、供应多样化和以患者为中心的服务的综合方法，我们降低了开发风险并加快了获取途径。

行业领导者应采取协调一致、风险平衡的方法，将科学策略与生产和市场进入计划相结合，以加速对患者的持久影响。首先，将生产的考量纳入早期临床试验设计决策，可降低后期供应受限的可能性，并有助于与监管机构就可比性和长期追踪进行更清晰的讨论。其次，企业应优先创建适应性证据，将可靠的临床终点与可操作的真实世界资料收集结合。这有助于支援产品的迭代改进，同时满足监管机构和支付方的需求。第三，供应商网路多元化和区域製造地建设可降低关税和跨境风险，而与经验丰富的生物製药生产商签订长期产能合约则可确保关键原材料的供应。

请描述一种混合方法分析方法，该方法结合了专家访谈、监管审查和供应链映射，以检验策略见解，而无需依赖数值化的市场规模估计。

本执行报告的基础研究采用混合方法，旨在全面了解Duchenne氏肌肉失养症治疗药物研发的科学、运作和商业性层面。主要研究包括对临床专家、生产专家、支付方顾问和患者权益组织代表进行结构化访谈，以检验治疗方法的具体挑战和证据预期。次要研究整合了同行评审文献、监管指导文件、临床试验註册资讯以及公司公开提交的文件，以梳理技术进展、安全性考虑和不断变化的试验终点。交叉检验阶段将访谈结果与已记录的证据进行比较，以确保一致性并减少偏差。

这整合了策略重点和营运要求，以决定Duchenne氏肌肉失养症治疗方面的科学进步是否会带来持续的临床益处和更广泛的患者群体。

总之，Duchenne氏肌肉失养症的治疗格局正处于一个关键的转折点，科学创新、生产现实和支付方的期望在此交汇，决定着哪些治疗方法能够惠及患者以及如何在临床实践中应用。外显子跳跃、基因治疗载体和优化类固醇疗法的进展具有改变疾病进程的真正潜力，但要实现这一潜力，需要研发、生产和商业化团队的协调规划。对可扩展生产设施的策略性投资、与监管机构和支付方的早期沟通、全面的真实世界数据（REW）计划以及健全的患者支持模式，将在将临床潜力转化为永续的患者可及性方面发挥至关重要的作用。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：Duchenne氏肌肉失养症治疗市场：依药物类别划分

  • 埃克森美孚跳过
  • 基因治疗
    • 基于腺结合病毒（AAV）
      • 血清型 6
      • 血清型 9
    • 非病毒
  • 类固醇疗法

第九章：Duchenne氏肌肉失养症治疗市场：依形式划分

  • 胶囊
  • 注射药物
  • 口服锭剂

第十章：Duchenne氏肌肉失养症治疗市场：依给药途径划分

  • 肌肉内部
  • 静脉
  • 口服

第十一章Duchenne氏肌肉失养症治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十二章Duchenne氏肌肉失养症治疗市场：依最终用户划分

  • 家庭医疗保健设施
  • 医院
  • 专科诊所

第十三章Duchenne氏肌肉失养症治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章Duchenne氏肌肉失养症治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章Duchenne氏肌肉失养症治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国Duchenne氏肌肉失养症治疗药物市场

第十七章：中国Duchenne氏肌肉失养症治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Anuh Pharma Limited
  • Arlak Biotech Pvt.Ltd.
  • Aurigene Pharmaceutical Services Ltd.
  • Bayer Pharmaceutical
  • Cipla Inc.
  • Enomark
  • Glasier Wellness, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Leo Pharma
  • Lifecare Neuro Products Limited
  • Mankind Pharma Ltd.
  • Merck & Co., Inc.,
  • MODASA Pharmaceuticals Pvt. Ltd.
  • Novartis AG
  • Pfizer Inc.
  • QndQ Derma
  • RayBiotech, Inc.
  • Ronyd Healthcare Pvt Ltd.
  • Sarepta Therapeutics, Inc.
  • Sumitomo Corporation
  • Texas Pharmaceuticals Pvt. Ltd.
  • Wellona Pharma
  • Zuventus Healthcare Ltd.
Product Code: MRR-5E3B35529469

The Duchenne Muscular Dystrophy Drugs Market was valued at USD 1.85 billion in 2025 and is projected to grow to USD 2.02 billion in 2026, with a CAGR of 9.31%, reaching USD 3.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.85 billion
Estimated Year [2026] USD 2.02 billion
Forecast Year [2032] USD 3.46 billion
CAGR (%) 9.31%

Setting the stage for Duchenne muscular dystrophy therapeutic strategies by summarizing scientific progress, clinical priorities, and stakeholder imperatives across the ecosystem

Duchenne muscular dystrophy remains one of the most clinically and commercially complex rare disease areas, characterized by progressive muscle degeneration, substantial caregiver burden, and a persistent need for disease-modifying therapies. Scientific advances over the past decade have shifted the field beyond symptomatic care toward targeted molecular interventions, creating a dense ecosystem of therapeutic modalities, regulatory interactions, and payer engagement strategies. Clinicians, families, and policymakers increasingly demand evidence not only of biological activity, but of meaningful functional benefit, long-term safety, and sustainable access models.

Against this backdrop, industry participants face a landscape that requires integrated thinking across discovery, clinical development, manufacturing, and commercialization. Emerging modalities such as exon skipping, gene replacement strategies using AAV vectors, and refined corticosteroid regimens each carry distinct scientific rationales, regulatory considerations, and operational footprints. Moreover, as precision medicine techniques refine patient selection and outcome measurement, stakeholders must balance innovation with scalable manufacturing and distribution approaches. This executive summary synthesizes those dimensions, providing context for strategic decisions and highlighting levers that can accelerate translation from pipeline to patient impact.

Unprecedented scientific, manufacturing, and value-based care shifts are reshaping clinical development, distribution, and reimbursement strategies for Duchenne therapeutics

The past several years have produced transformative shifts that are redefining how Duchenne therapies are developed and delivered, with consequences for trial design, manufacturing, and long-term care models. Scientific innovations have enabled more precise targeting of the genetic defects underpinning the disease, prompting a move away from one-size-fits-all approaches toward modality-specific development paths that require bespoke regulatory and manufacturing strategies. Concurrently, measurement science has matured: novel functional endpoints, digital biomarkers, and patient-reported outcomes are being integrated into pivotal development programs to capture clinically meaningful benefit in smaller, more heterogeneous populations.

Operationally, the industry is experiencing a parallel transition. Gene-based therapeutics reliant on AAV vectors are driving urgent investments in vector manufacturing capacity, quality control, and long-term safety monitoring systems. The choice of serotype, such as AAV6 or AAV9, now influences distribution kinetics, tissue tropism, and manufacturing complexity, which in turn affects clinical strategy and commercial viability. At the same time, exon skipping agents and optimized corticosteroid approaches continue to be refined, offering differentiated profiles in terms of administration, monitoring, and patient populations. These technological and procedural shifts are fostering new partnerships between biotech innovators, contract manufacturers, and specialty pharmacies, while also prompting payers and health systems to explore outcomes-based reimbursement and risk-sharing models to manage high upfront costs with uncertain long-term benefit trajectories.

Taken together, these shifts demand that industry leaders integrate scientific, manufacturing, and commercial planning earlier in development to de-risk late-stage programs and align stakeholder expectations around real-world evidence collection and patient access.

Assessing how anticipated United States tariff adjustments in 2025 may influence supply chains, manufacturing localization choices, and commercial access strategies for Duchenne therapies

Trade policy changes and tariff considerations have become material factors in strategic planning for biopharma supply chains, and proposed tariff adjustments in the United States during 2025 represent an additional variable for companies operating in the Duchenne therapeutic space. Raw materials for biologics production, including plasmid DNA, specialized reagents, single-use systems, and AAV manufacturing inputs, often cross borders multiple times during the manufacturing lifecycle. Consequently, tariffs or customs reclassifications can increase landed costs, extend lead times, and create incentives to re-evaluate supplier footprints.

In response, organizations are reassessing near-term sourcing strategies and exploring diversification to mitigate exposure. Some are accelerating investments in localized production capacity or entering long-term supply agreements to lock predictable pricing and prioritize capacity allocation. These strategic choices have knock-on effects: onshoring or regionalizing production can reduce exposure to import duties but may require significant capital expenditure and time to qualify new manufacturing sites under stringent regulatory frameworks. Moreover, increased import costs can influence pricing discussions with payers and government purchasers, intensifying pressure to demonstrate durable clinical benefit and cost-effectiveness.

Importantly, higher cross-border costs also elevate the value of supply chain transparency and inventory optimization, prompting firms to adopt more sophisticated forecasting, demand-sensing, and buffer stock policies. Regulatory and customs compliance teams will need to engage earlier in project planning to avoid unexpected classification changes that trigger tariffs. Overall, while tariffs are only one of many commercial variables, their cumulative impact can shape manufacturing strategies, partner selection, and the economics of bringing advanced Duchenne therapies to diverse markets.

Deriving practical commercial and clinical implications by integrating drug class, distribution channel, end-user context, form factors, and administration routes into segmentation-driven strategy

Segmentation analysis reveals distinct strategic implications when therapies are examined through multiple clinical and commercial lenses. When viewed by drug class, exon skipping agents, gene therapy approaches, and steroid regimens each demand unique clinical development paradigms and evidence packages; within gene therapy, the division between AAV-based and nonviral modalities affects vector selection, immunogenicity management, and manufacturing pathway decisions, while further consideration of AAV serotype choices such as serotype 6 and serotype 9 drives tissue targeting, dosing strategy, and production scale complexity. Examining distribution channels highlights the varying logistical and compliance requirements across hospital pharmacies, online pharmacies, and retail pharmacies, with each channel posing different cold-chain, reimbursement capture, and patient support needs. From an end-user perspective, the demands of home healthcare settings contrast sharply with hospital and specialty clinic environments, affecting training, monitoring cadence, and emergency preparedness for infusion-related events. Form and route of administration are central to adoption and patient adherence; capsules and oral tablets enable different patient journeys than injectables or intravenous administrations, and intramuscular, intravenous, and oral routes each carry specific clinical monitoring and administration infrastructure requirements.

Synthesizing these segmentation axes underscores that portfolio design cannot be siloed. For example, a gene replacement candidate using AAV9 intended for hospital-based intravenous administration will require different commercialization investments than an orally administered steroid therapy distributed through retail pharmacies for home use. Therefore, go-to-market planning must align clinical designs with downstream distribution, payer engagement, and patient-support services early in development. This integrated perspective enables tailored value propositions that reflect real-world use cases, reduce adoption friction, and support compelling evidence generation strategies for regulators and payers alike.

Evaluating regional regulatory, reimbursement, and operational nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform phased market entry and access strategies

Regional dynamics will shape the deployment and access pathways for Duchenne therapies, and each geography presents distinct regulatory, reimbursement, and operational considerations. In the Americas, there is a mature network of specialized centers, established rare disease clinical trial infrastructure, and payers that emphasize health technology assessment and value-based arrangements, which collectively influence the sequencing of approvals and commercial launches. In Europe, Middle East & Africa, regulatory pathways are diverse and reimbursement decision-making frequently involves national authorities with differing expectations for comparative effectiveness evidence, necessitating early alignment on heterogenous evidence strategies and localized health economic modeling. The Asia-Pacific region presents rapidly evolving clinical research capacity, a growing appetite for industry partnerships, and varied manufacturing ecosystems; however, market access strategies must account for divergent regulatory requirements, pricing controls, and patient access programs.

Consequently, regional strategies should prioritize flexible regulatory pathways, phased market entry plans, and partnerships that leverage local clinical expertise and distribution networks. Cross-border logistical planning is particularly important for advanced therapies with cold-chain or clinic-based administration needs, and regional manufacturing hubs can mitigate tariff or import vulnerabilities while supporting faster patient access. Ultimately, understanding these regional nuances enables more precise stakeholder engagement and increases the likelihood of early adoption by aligning product delivery models with local healthcare delivery architectures.

Analyzing how company strategies around vector engineering, manufacturing scale-up, and stakeholder engagement determine clinical progression and commercial readiness in Duchenne therapeutics

Company-level dynamics are pivotal in shaping the pace and direction of innovation in Duchenne therapeutics. Biotech firms focusing on exon skipping and small-molecule approaches continue to refine payload chemistry, delivery optimization, and patient-selection criteria to enhance clinical differentiation. Organizations pursuing gene replacement therapies are concentrating on vector engineering, serotype selection, and scalable GMP manufacturing to reduce batch-to-batch variability and support consistent clinical supply. Across the industry, strategic alliances-whether through research collaborations, licensing deals, or manufacturing partnerships-are frequently used to bridge capability gaps and accelerate time to clinic.

Investor and corporate priorities are also evolving: there is greater emphasis on operational execution, late-stage safety monitoring plans, and commercial readiness in parallel with clinical milestones. Companies with integrated strategies that align clinical development with manufacturing scale-up and payer engagement tend to navigate late-stage inflection points more effectively. In addition, patient advocacy groups and clinician networks are powerful conveners, influencing trial recruitment, endpoint selection, and post-approval evidence generation, so companies that invest in transparent stakeholder engagement and patient support infrastructure can strengthen both trial enrollment and long-term uptake. Finally, organizations that proactively address manufacturing capacity, supply chain resilience, and regulatory pathways are better positioned to translate R&D successes into accessible therapies for patients.

Adopt integrated actions linking early manufacturing planning, adaptive evidence generation, supply diversification, and patient-centered services to de-risk development and accelerate access

Industry leaders should adopt a coordinated, risk-balanced approach that links scientific strategy with manufacturing and market access planning to accelerate sustainable patient impact. Firstly, integrating manufacturing considerations into early clinical design decisions reduces the likelihood of late-stage supply constraints and enables clearer discussions with regulators about comparability and long-term follow-up. Secondly, firms should prioritize adaptive evidence generation that combines robust clinical endpoints with pragmatic real-world data collection to meet the needs of regulators and payers while supporting iterative product improvements. Thirdly, diversifying supplier networks and exploring regional manufacturing hubs can mitigate tariff and cross-border risks, while long-term capacity agreements with experienced biologics manufacturers can secure critical inputs.

Furthermore, investment in patient-centric services and digital monitoring platforms can improve adherence, capture meaningful outcomes, and strengthen value discussions with payers. Engaging patient advocacy groups early and transparently augments recruitment and aligns development programs with daily life improvements that matter to families. Lastly, leaders should pursue strategic partnerships-spanning research institutions, contract manufacturers, and specialty distribution channels-to fill capability gaps and accelerate time to broader access. Implementing these actions in concert will create a more resilient, evidence-driven approach to bringing transformative Duchenne therapies to patients.

Describe the mixed-methods analytical approach combining expert interviews, regulatory reviews, and supply chain mapping to validate strategic insights without relying on numerical market sizing

The research underpinning this executive synthesis utilized a mixed-methods approach to capture scientific, operational, and commercial dimensions relevant to Duchenne therapeutic development. Primary research included structured interviews with clinical experts, manufacturing specialists, payer advisors, and patient advocacy representatives to validate modality-specific challenges and evidence expectations. Secondary research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly disclosed corporate filings to map technology trajectories, safety considerations, and trial endpoint evolution. Cross-validation steps compared insights from interviews with documentary evidence to ensure consistency and reduce bias.

Analytical methods emphasized qualitative triangulation and scenario-based risk assessment rather than quantitative market sizing. Special attention was given to supply chain mapping for biologics manufacturing and to evaluating the interplay between serotype selection and clinical strategy for gene therapies. Wherever applicable, regulatory precedent and published long-term follow-up frameworks informed the assessment of post-market evidence needs. Limitations include the evolving nature of clinical data and policy environments; consequently, readers are advised to consider these findings alongside emerging trial results and regulatory decisions as they become available.

Synthesize strategic priorities and execution imperatives that will determine whether scientific advances in Duchenne therapies translate into durable clinical benefit and broad patient access

In conclusion, the Duchenne therapeutic landscape is at a pivotal juncture where scientific innovation, manufacturing realities, and payer expectations converge to shape which therapies reach patients and how they are adopted in practice. Progress in exon skipping, gene therapy vectors, and optimized steroid regimens offers real potential to alter disease trajectories, but realizing that potential depends on synchronized planning across R&D, manufacturing, and commercial teams. Strategic investments in scalable manufacturing, early engagement with regulators and payers, comprehensive real-world evidence plans, and robust patient support models will be decisive in translating clinical promise into sustainable patient access.

As stakeholders navigate tariff policies, regional regulatory heterogeneity, and evolving evidence standards, flexibility and proactive stakeholder alignment will differentiate organizations that can rapidly convert scientific breakthroughs into durable clinical and commercial outcomes. The path forward requires integrated execution, transparent engagement with patient communities, and adaptive evidence strategies that prioritize measured benefit for patients while addressing the long-term sustainability of therapeutic access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Duchenne Muscular Dystrophy Drugs Market, by Drug Class

  • 8.1. Exon Skipping
  • 8.2. Gene Therapy
    • 8.2.1. Aav Based
      • 8.2.1.1. Serotype 6
      • 8.2.1.2. Serotype 9
    • 8.2.2. Nonviral
  • 8.3. Steroid Therapy

9. Duchenne Muscular Dystrophy Drugs Market, by Form

  • 9.1. Capsule
  • 9.2. Injectable
  • 9.3. Oral Tablet

10. Duchenne Muscular Dystrophy Drugs Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Intravenous
  • 10.3. Oral

11. Duchenne Muscular Dystrophy Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Duchenne Muscular Dystrophy Drugs Market, by End User

  • 12.1. Home Healthcare Settings
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Duchenne Muscular Dystrophy Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Duchenne Muscular Dystrophy Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Duchenne Muscular Dystrophy Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Duchenne Muscular Dystrophy Drugs Market

17. China Duchenne Muscular Dystrophy Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anuh Pharma Limited
  • 18.6. Arlak Biotech Pvt.Ltd.
  • 18.7. Aurigene Pharmaceutical Services Ltd.
  • 18.8. Bayer Pharmaceutical
  • 18.9. Cipla Inc.
  • 18.10. Enomark
  • 18.11. Glasier Wellness, Inc.
  • 18.12. GlaxoSmithKline PLC
  • 18.13. Johnson & Johnson Services, Inc.
  • 18.14. Leo Pharma
  • 18.15. Lifecare Neuro Products Limited
  • 18.16. Mankind Pharma Ltd.
  • 18.17. Merck & Co., Inc.,
  • 18.18. MODASA Pharmaceuticals Pvt. Ltd.
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. QndQ Derma
  • 18.22. RayBiotech, Inc.
  • 18.23. Ronyd Healthcare Pvt Ltd.
  • 18.24. Sarepta Therapeutics, Inc.
  • 18.25. Sumitomo Corporation
  • 18.26. Texas Pharmaceuticals Pvt. Ltd.
  • 18.27. Wellona Pharma
  • 18.28. Zuventus Healthcare Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY EXON SKIPPING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 6, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SEROTYPE 9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STEROID THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOME HEALTHCARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 144. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 145. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GCC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 168. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 169. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. G7 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 176. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 177. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. NATO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GENE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AAV BASED, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)